At 23.5x earnings with 1.97% ROIC, Regeneron asks owners to pay growth prices for value destruction.

This framework sees a biotech burning cash on R&D while insiders flee, yet still commanding a premium valuation—the antithesis of Buffett's certainty principle.

If you bought this entire business today, would what it earns justify what you paid?

At $483, an owner gets a 1.06% earnings yield while treasuries pay 4.33%—paying a premium for a business with 1% revenue growth. The 61.3% discount to DCF suggests the market expects very little, but this framework asks why pay 23.5x earnings for such modest expectations.

Can the company deploy retained capital at high rates of return?

This framework sees value destruction—every dollar reinvested earns less than its cost. The collapse from 14.96% to 1.97% ROIC while pouring 138.9% of cash flow into R&D suggests the incremental returns on massive research spending have turned negative.

Are insiders buying or selling? Is capital invested where returns are high?

This framework sees troubling stewardship—insiders selling consistently for five years while management buys back shares now 84.4% underwater. The combination of persistent insider selling with poorly-timed buybacks suggests those who know the business best lack confidence in capital allocation decisions.

Does this company have an enduring competitive advantage that protects returns on capital?

This framework sees a narrow moat dependent on partnerships—while 84.9% gross margins suggest pricing power, the 51.1% collaboration revenue dependence and high concentration risk indicate the moat relies more on partner relationships than proprietary advantages. Stable margins provide some comfort, but the partnership dependence limits durability.

How much cash does an owner actually receive after maintaining the business?

This framework sees reasonable cash generation—$922 million quarterly FCF demonstrates the business produces real cash despite heavy R&D. However, 6.4% SBC dilution and a 481-day cash cycle suggest owners receive less than accounting earnings imply.

Applying this framework to Regeneron reveals a biotech spending like a startup while growing like a utility—138.9% of cash flow on R&D for 1% revenue growth. With ROIC below cost of capital and insiders selling for 20 straight quarters, this represents everything the framework avoids: uncertain returns, deteriorating economics, and management lacking skin in the game. Why would a rational owner pay 23.5x earnings for a business where those who know it best are heading for the exits?

This analysis applies Warren Buffett's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Warren Buffett. Educational purposes only. Not financial advice.